Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer

Verastem Oncology developed its drug combination for low-grade serous ovarian cancer (LGSOC) driven by KRAS mutations. As the first treatment specifically approved for this rare cancer, clinicians expect it will become the new standard of care. The post Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer appeared first…

Read More

Who Will Pay If ACA Tax Credits Lapse?

About 22 million Americans would face sharply higher healthcare costs if enhanced ACA tax credits expire at the end of the year. Experts warn that the impact would extend beyond just families relying on ACA courage — also straining hospitals, increasing uncompensated care and potentially costing the economy hundreds of thousands of jobs. The post…

Read More

RFK Jr. Cancels $500M in mRNA R&D Contracts as HHS Turns Focus to Older, Slower Vaccine Technologies

Health and Human Services Secretary Robert F. Kennedy Jr. is cancelling 22 mRNA vaccine contracts funded by BARDA. Without evidence, Kennedy claimed these vaccines fail to protect effectively against upper respiratory tract infections. The post RFK Jr. Cancels $500M in mRNA R&D Contracts as HHS Turns Focus to Older, Slower Vaccine Technologies appeared first on…

Read More

ISPOR 2025 Award Winners

ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…

Read More